Key Concepts & Self-Assessment20 Key Facts
Review key Organoids: 3D Lab-Grown Miniature Organs, Stem Cell Self-Organization & Drug Testing exam facts and rate your mastery to track revision.
Progress: 0/20 Rated 0 Mastered 0 Review Later
#1
An organoid is a three-dimensional in vitro tissue culture derived from stem cells that replicates organ micro-anatomy, cell lineage diversity, and biological functions.
#2
Stem cell sources for organoid generation include adult stem cells, embryonic stem cells, and induced pluripotent stem cells reprogrammed with Yamanaka transcription factors.
#3
Extracellular matrix hydrogels, most frequently basement membrane extract known as Matrigel, provide structural anchorage and biochemical cues for stem cell self-organization.
#4
Dutch scientist Hans Clevers and Toshiro Sato created the first adult stem cell-derived intestinal organoids in 2009 at the Hubrecht Institute.
#5
Intestinal organoid cultivation demonstrated that isolated Lgr5-positive adult crypt cells self-organize into self-renewing crypt-villus epithelial architectures without requiring an underlying mesenchymal feeder layer.
#6
Signaling morphogens regulating organoid differentiation include epidermal growth factor, bone morphogenetic protein inhibitor Noggin, and canonical Wnt pathway agonist R-spondin.
#7
In 2011, Japanese stem cell biologist Yoshiki Sasai pioneered self-organizing synthetic optic cups, recapitulating human retinal neurogenesis inside three-dimensional suspension cultures.
#8
Madeline Lancaster established human cerebral organoids in 2013, enabling researchers to model cortical development and elucidate Zika virus microcephaly pathogenic mechanisms.
#9
Organoids differ from microfluidic organ-on-a-chip platforms because organoids develop through autonomous cellular self-organization rather than synthetic micro-engineered physical fluid flow constraints.
#10
Patient-derived tumor organoids replicate individual oncological histology and mutational profiles, operating as high-fidelity preclinical platforms for personalized anti-cancer drug screening assays.
#11
The United States FDA Modernization Act 2.0 authorized organoids and cell-based platforms as legally valid alternatives to traditional animal toxicity testing protocols.
#12
India amended the New Drugs and Clinical Trials Rules in 2023, validating organoid platforms for preclinical testing of investigational new pharmaceutical agents.
#13
Organoids model genetic monogenic disorders effectively, exemplified by evaluating cystic fibrosis transmembrane conductance regulator modulator drugs using rectal epithelial organoid swelling assays.
#14
A primary technical limitation of current organoid platforms is the absence of functional vascular networks, restricting tissue growth and long-term metabolic survival.
#15
Immune cell deficiency in classical organoid cultures prevents complete immune-mediated pathology modeling, prompting researchers to develop co-culture systems with autologous lymphocytes.
#16
CRISPR-Cas9 gene editing integrated into organoid protocols allows scientists to introduce specific hereditary mutations and evaluate targeted phenotypic corrections in human tissues.
#17
Kidney organoids grown from human pluripotent stem cells develop interconnected nephron-like compartments comprising glomeruli, proximal tubules, and distal tubule segments.
#18
Liver organoids simulate hepatic metabolic detoxification pathways, providing accurate predictive screening metrics for drug-induced liver injury during early pharmaceutical candidate evaluation.
#19
Bio-printing innovations combine sacrificial biomaterial lattices with stem cells to fabricate vascularized organoid constructs displaying extended cellular viability and tissue differentiation.
#20
Organoid biobanks preserve patient-specific living tissues across long durations, enabling retrospective pharmacological evaluations and collaborative biomedical research without repetitive invasive tissue biopsies.
Subject Specialist Commentary
Analytical perspective & practical exam advice from the Master10 academic board
Organoid technology marks a transformative milestone across contemporary biomedical science, bridging cellular biology with systemic pharmacology. By faithfully recreating three-dimensional organ structures in vitro, organoids eliminate critical translational discrepancies inherent in traditional animal models. Civil service examinations frequently test stem cell classifications, Hans Clevers's intestinal experiments, and legal frameworks replacing animal trials. Understanding differences between self-assembling organoids and micro-fabricated organ-on-a-chip devices equips candidates with substantial analytical depth for general science questions.
Recent regulatory milestones, such as India's 2023 clinical trial reforms and the American FDA Modernization Act 2.0, emphasize the industrial maturation of this technology. Students should emphasize organoid utility in personalized chemotherapy selection, infectious disease modeling, and drug toxicology screening. Remembering developmental mechanics clarifies complex laboratory tissue culture protocols. Remember the S-T-E-M mnemonic: Stem cells Trigger Extracellular-guided Morphogenesis, creating three-dimensional organoid architectures for targeted preclinical therapeutic evaluation.
Related Knowledge Topics to Discover
Looking for more GK practice?
Explore 52,789+ questions across 65 General Knowledge categories.